more patients on the new anticoagulant dabigatran (Pradaxa) instead of warfarin for nonvalvular atrial fibrillation
January 2011
You'll see more patients on the new anticoagulant dabigatran (Pradaxa) instead of warfarin for nonvalvular atrial fibrillation.
It's not just because dabigatran doesn't need monitoring. Dabigatran also prevents more strokes than warfarin...about 5 more strokes per 1000 patients per year...with a similar OVERALL bleeding risk.
Some insurers now cover it WITHOUT a prior authorization...and Canadian guidelines already recommend it OVER warfarin for A fib.
Get concise, unbiased advice for effective drug therapy, plus CE/CME
Prescriber Insights: APRN includes:
- Cutting-edge advice about new medications and how they fit into practice
- Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
- Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations
Already a subscriber? Log in
Volume pricing available. Get a quote